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Background. Randomized controlled trials testing the association between vitamin D status and upper respira-
tory tract infection (URTI) have given mixed results. During a multicenter, randomized controlled trial of colorectal
adenoma chemoprevention, we tested whether 1000 IU/day vitamin D3 supplementation reduced winter episodes
and duration of URTI and its composite syndromes, influenza-like illness (ILI; fever and ≥2 of sore throat, cough,
muscle ache, or headache) and colds (no fever, and ≥2 of runny nose, nasal congestion, sneezing, sore throat,
cough, swollen or tender neck glands).
Methods. The 2259 trial participants were aged 45–75, in good health, had a history of colorectal adenoma, and
had a serum 25-hydroxyvitamin D level ≥12 ng/mL. They were randomized to vitamin D3 (1000 IU/day), calcium
(1200 mg/day), both, or placebo. Of these, 759 participants completed daily symptom diaries. Secondary data in-
cluded semiannual surveys of all participants.
Results. Among those who completed symptom diaries, supplementation did not significantly reduce winter
episodes of URTI (rate ratio [RR], 0.93; 95% confidence interval [CI], .79–1.09) including colds (RR, 0.93; 95% CI,
.78–1.10) or ILI (RR, 0.95; 95% CI, .62–1.46), nor did it reduce winter days of illness (RR, 1.13; 95% CI, .90–1.43).
There was no significant benefit according to adherence, influenza vaccination, body mass index, or baseline vitamin D
status. Semiannual surveys of all participants (N = 2228) identified no benefit of supplementation on ILI (odds ratio [OR],
1.14; 95% CI, .84–1.54) or colds (OR, 1.03; 95% CI, .87–1.23).
Conclusions. Supplementation with 1000 IU/day vitamin D3 did not significantly reduce the incidence or dura-
tion of URTI in adults with a baseline serum 25-hydroxyvitamin D level ≥12 ng/mL.
Keywords. upper respiratory tract infection; vitamin D; randomized controlled trial.
Upper respiratory tract infections (URTIs) are a fre-
quent cause of illness, with an estimated 500 million
episodes annually in the United States, and an
economic burden of $40 billion [1]. Most colds are
mild, but influenza and influenza-like illness (ILI),
characterized by high fever, headache, and myalgia,
account for approximately 9% of URTIs and affect one-
fifth of the US population annually, causing 226 000
hospitalizations and 36 000 deaths [2].
In 1926, Smiley hypothesized that the seasonality of
URTI was due to fluctuations in the “vitamine” found
in dairy foods and produced in humans on sunlight ex-
posure [3]. Others have since reiterated variations of
this hypothesis [4, 5]. Although observational studies
show an inverse association between vitamin D status
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and URTI risk [6–8], the few randomized controlled trials
(RCTs) of vitamin D supplementation and respiratory infection
have yielded mixed results [9–20].
Evidence from animal models and human observational
studies suggested that vitamin D may inhibit carcinogenesis
[21–22]. We therefore conducted a large RCT of vitamin D3
and calcium chemoprevention of colorectal adenoma. During
the trial, we investigated whether vitamin D3 supplementation
(1000 IU/day) would reduce the number of episodes and dura-
tion of URTI in winter and throughout the year, and the
number of episodes and duration of winter ILI and of colds.
METHODS
We conducted a randomized, double-blind, placebo-controlled
multicenter trial of supplementation with vitamin D3 (1000
IU/day) and/or calcium carbonate (1200 mg elemental
calcium/day) for the prevention of large-bowel adenomas.
Participants recruited from May 2004 through November
2008 at 11 clinical centers had at least 1 colorectal adenoma re-
cently removed and none remaining after complete colonosco-
py. Eligible participants were 45–75 years old, in good general
health with no contraindications to study treatment, and had
no familial colorectal cancer syndromes or history of serious
intestinal disease. Individuals with serum vitamin D levels
<12 ng/mL were excluded. All participants provided written
informed consent; the research was approved by institutional
review boards at each clinical center.
A detailed health questionnaire was administered at enroll-
ment. Participants agreed to avoid taking vitamin D supple-
ments outside the trial, although after April 2008, recognizing
the increasing use of vitamin D supplementation in the com-
munity and its potential impact on study retention, the study
procedures were revised to allow personal supplementation of
up to 1000 IU/day vitamin D while continuing randomized
treatment. Enrollment was followed by a placebo run-in period
of 56–84 days to identify and exclude before randomization
participants who were unlikely to be adherent, including those
who had taken <80% of study pills. Study treatment was sched-
uled to continue until the surveillance colonoscopy either 3 or
5 years after the qualifying examination, according to recom-
mendations by each participant’s gastroenterologist.
Eligibility for randomization after the run-in period was con-
firmed by blinded coordinators, and a web-based, random
number generator assigned treatment within blocks, stratified
by study center, sex, and colonoscopy interval (3 or 5 years) in
a modified 2 × 2 factorial design to identical-looking pills con-
taining vitamin D3, calcium carbonate, both, or placebo (“4-arm
study”). Women who declined to forego calcium supplementa-
tion were randomized to calcium alone or calcium plus vitamin
D (“2-arm study”). Participants and investigators were blinded;
the computer programming staff, 1 pharmacy technician, sta-
tistician, and statistical analyst were unblinded.
After randomization, all participants were telephoned every
6 months to assess adherence to study agents, illness, and use
of medications and supplements. In September 2007, we added
a question to assess a secondary endpoint in all participants:
“Have you had a cold in the last 2 weeks? (By a cold, we mean
at least 2 of the following: runny nose, congestion, sneezing,
sore throat, dry cough, or swollen or tender neck glands, lasting
for at least 2 days, and which was not caused by allergies).” In
December 2009, in response to the H1N1 pandemic of April
2009–August 2010, we added a question to assess an additional
secondary endpoint: “Since your last study questionnaire, have
you had the flu or an influenza-like illness (fever plus 2 or more
of the following: sore throat, cough, muscle ache, headache)?”
Responses through September 2012 were analyzed.
Serum was tested for 25-hydroxyvitamin D [25(OH)D] at
enrollment, 1 year after randomization, and 3 years after ran-
domization for participants with a 5-year colonoscopy surveil-
lance cycle. We measured 25(OH)D using the IDS (Fountain
Hills, Arizona) liquid phase radioimmunoassay kit.
Beginning in November 2009, participants with at least 6
months remaining on study were invited to participate in a
“Colds and Flu” (CAF) substudy (Figure 1) by completing daily
health diaries regarding fever, headache, muscle aches, chills,
cough, runny nose, and allergies. Information was also collect-
ed each month on influenza and pneumococcal vaccines, anti-
biotics and antiviral medications, and medical care sought for
URTI symptoms. Initially, all diaries were completed on paper
while a web-based application was being programmed; the
web-based option was also offered in June 2010. In summer
2010, because we had not reached our target enrollment of 800
participants, we asked existing participants to continue com-
pleting health diaries for a second winter season through
March 2011 or until 2 months after the end of treatment. Par-
ticipants were compensated $5 for reviewing informational ma-
terials and $5 for each completed diary.
Definitions and Assumptions
URTI was defined as either a cold or ILI. ILI was any episode
with at least 1 day of fever (≥100°F [37.8°C] or participants
reported feeling hot) and ≥2 of sore throat, cough, muscle ache,
or headache [23]. A cold required absence of ILI and ≥2 of the
following on a single day: runny nose, nasal congestion, sneez-
ing, sore throat, cough, and swollen or tender neck glands.
Three seasons were defined: winter 1 (1 November 2009–31
March 2010), nonwinter (1 April 2010–31 October 2010), and
winter 2 (1 November 2010–31 March 2011). We defined the
start of an episode as the first day the syndrome case definition
was fulfilled, provided the preceding 6 days were syndrome-free
or not recorded [24]; if a day with symptoms occurred within
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6 days of a previous episode, it was considered to be part of the
previous episode. Episodes were attributed to the season in
which they began. Days of moderate illness were those fulfilling
the definition of a cold but not ILI, even if part of an ILI
episode; days of severe illness fulfilled the definition of ILI.
We defined optimal trial adherence as the reported taking of
at least 80% of study pills during the CAF period, no personal
vitamin D supplementation, and no gaps in pill-taking of ≥7
days.
For each year, illness episodes in participants vaccinated
before November were compared with those who received no
influenza vaccination from August through March. Participants
receiving vaccine during the 2 winters (November through
March) were excluded from that analysis. If >1 vaccination date
was reported, we used the earliest.
Subjects were allocated into 8 subgroups of baseline vitamin
D exposure according to the season of enrollment (winter/
spring or summer/fall) and supplemental vitamin D intake at
enrollment (>400 IU, 201–400 IU, 1–200 IU, or none). We cal-
culated tertiles of 25(OH)D for each subgroup and used these
to rank each CAF participant’s vitamin D status within their
subgroup. Participants with the same rank were pooled and the
effect of supplementation evaluated separately for those with
low, medium, or high baseline vitamin D status.
Statistical Analysis
Assuming 800 participants would participate for 1 year, and
that placebo participants would experience 0.6–0.9 episodes
and 1–3 days ill with winter URTI per year on average [1], we
estimated we could detect a rate ratio of ≤0.7 for the number of
episodes (power >90%), and ≤0.8 for the number of days ill
(power >80%), with a 2-sided, 5% significance level.
We computed rate ratios with 95% confidence intervals
(CIs) for illness episodes among participants randomized to
Figure 1. CONSORT (Consolidated Standards of Reporting Trials) flow diagram. Abbreviation: 25(OH)D, 25-hydroxyvitamin D.
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vitamin D vs placebo, using generalized estimating equations
(GEEs) with robust Poisson errors and exchangeable correlation
matrices to adjust for overdispersion. Season-specific rates
were estimated using person-years of observation during that
season—for example, 1 episode during 4 winter months is
equivalent to 3 episodes per person-year. Days of illness were
frequently zero, so GEEs with negative binomial errors were
used for these rate ratios. Analyses were adjusted for calcium
treatment and the stratifying variables center, colonoscopy sur-
veillance interval (3 or 5 years), a 3-category term for sex and
participation in the 4- or 2-arm study, and season (winter1,
winter 2, and other). We also analyzed the associations between
symptoms and serum 25(OH)D on treatment, independent of
randomized treatment assignment, adjusting for variables that
were significant predictors of baseline serum level.
Analyses were conducted using Stata version 12 [25] accord-
ing to intent-to-treat except as indicated. Sensitivity analyses to
explore effects of missing data and episode definitions are de-
scribed in the Supplementary Appendix.
RESULTS
We identified 19 083 patients potentially eligible for the parent
trial; 2813 were enrolled and 2259 were randomized (Figure 1,
Table 1). Of the 2259 randomized participants, 1198 (53.0%)
were invited to complete health diaries, and 759 (63.4%) re-
turned at least 1 correctly completed diary (Figure 1, Table 1).
The mean numbers of diaries returned were similar between
the groups. In the most recent telephone survey before partici-
pants’ first health diaries, 660 of 759 (87.0%) reported having
taken at least 85% of study pills; 77.7% were classified as opti-
mally adherent during the CAF substudy period. The relative
increase in 25(OH)D associated with supplementation was 8.7
ng/mL in substudy participants and 7.8 ng/mL in all partici-
pants (Table 1).
During winter months, CAF substudy participants reported
on average 0.25 episodes of URTI per month of observation
(Table 2); 28.6% of participants reported none. There were no
significant differences between treatment groups in episodes
of URTI (rate ratio [RR], 0.93; 95% confidence interval [CI],
.79–1.09), colds (RR, 0.93; 95% CI, .78–1.10), or ILI (RR, 0.95;
95% CI, .62–1.46) in winter, nor over the entire 17-month CAF
period (Table 2). During winter, the mean number of days of
URTI was 1.8 per person-month in the vitamin D group and
1.6 per person-month in the placebo group (RR, 1.13; 95% CI,
.90–1.43), with no significant differences in moderate or severe
days ill. Calcium supplementation was not associated with inci-
dence or duration of any of the 3 syndromes, nor did it modify
the vitamin D treatment effect (not shown). Similar results
were seen in winter 1 and winter 2 (during and after the H1N1
pandemic, respectively; data not shown).
A variety of secondary and sensitivity analyses were conduct-
ed (Supplementary Data). The effect of vitamin D supplemen-
tation on episodes or days of illness was not significantly
modified by 25(OH)D status at enrollment. In particular, sup-
plementation did not significantly protect against winter URTI
episodes among participants with the lowest baseline vitamin
D (RR, 0.82; 95% CI, .62–1.10). There was no statistically signif-
icant modification of the effect of vitamin D by influenza vacci-
nation, adherence, or body mass index, on either episodes or
days of illness, although there were nonsignificant protective
effects on severe illness when analyses were restricted to the un-
vaccinated group, the optimally adherent, and the obese (Sup-
plementary Table 1). There were no significant differences
between treatment groups, during winter or overall, in the pro-
portions of participants who sought medical help for their
symptoms or were prescribed antibiotics or antiviral medicines.
Sensitivity analyses did not change these conclusions.
Among all participants in the parent trial, semiannual tele-
phone surveys identified an episode of ILI since the previous
survey among 9.5% of the vitamin D group and 8.6% of the
placebo group (adjusted odds ratio [OR], 1.14; 95% CI, .84–
1.54; Table 2). A cold in the previous 2 weeks was reported on
at least 1 survey by 38.1% of participants in the vitamin D
group and 37.5% in the placebo group (OR, 1.03; 95% CI, .87–
1.23). Similar results were seen after restricting the analysis to
the participants and timeframe of the CAF study (November
2009–March 2011; data not shown).
The mean serum levels measured closest in time to the start
of the CAF study showed no significant differences between
those who did and those who did not report colds or ILI during
all telephone interviews (colds: 28.0 and 27.8 ng/mL; ILI: 27.3
and 27.9 ng/mL, respectively) or winter health diaries (URTI:
29.7 and 29.1 ng/mL) (all P > .10). In an observational analysis,
the risk of URTI based on quartiles of serum 25(OH)D suggest-
ed a significantly higher risk of ILI (but not colds) in the lowest
quartile of serum 25(OH), and a similar association with the
number of days of severe (but not moderate) illness, after ad-
justment for multiple factors not including randomized treat-
ment (Table 3).
DISCUSSION
We found no evidence that 1000 IU/day vitamin D3 supple-
mentation reduced episodes or duration of URTI during a large
randomized, placebo-controlled chemoprevention trial of older
adults. Our results were consistent when measured through de-
tailed daily health diaries in a subset of 759 participants, or via
simple, periodic surveys of all participants. We found no signif-
icant associations either during the first winter, which over-
lapped with the 2009–2010 H1N1 influenza pandemic, or the
second winter after the pandemic. Vitamin D supplementation
Vitamin D and Upper Respiratory Infection • CID 2013:57 (15 November) • 1387
conferred no significant protection against colds, ILI, or any
URTI overall, nor among those with the lowest baseline serum
25(OH) vitamin D, although participants whose baseline
concentration was <12 ng/mL were specifically excluded from
our trial. Our results were statistically nonsignificant during the
winter and over all seasons.
Table 1. Characteristics of Participants Who Provided Cold and Influenza-like Illness Data
Characteristic
Participants, No. (%)
Polyp Prevention Studya Colds and Flu Substudyb
Vitamin D Placebo Vitamin D Placebo
n = 1130 n = 1129 n = 399 n = 360 P Valuec
Age at enrollment, y, mean (SD) 58.1 (6.9) 58.0 (6.8) 57.9 (6.7) 57.8 (6.3) .89
Age as of 1 November 2009, mean (SD) 61.5 (7.0) 61.3 (6.9) 60.7 (6.7) 60.5 (6.4) .78
Male sex 712 (63.0) 711 (63.0) 237 (59.4) 201 (55.8) .32
Race .22
White 951 (88.1) 949 (87.8) 352 (90.5) 309 (88.8)
Black 96 (8.9) 88 (8.1) 27 (6.9) 26 (7.5)
Asian 25 (2.3) 26 (2.4) 9 (2.3) 7 (2.0)
Other 7 (28.0) 18 (1.7) 1 (0.3) 6 (1.7)
Missing 51 48 10 12
Hispanic ethnicity 76 (6.7) 70 (6.2) 20 (5.0) 22 (6.1) .50
Missing 1 2 0 1
Body mass index at enrollment, kg/m2
Mean 28.9 (5.0) 29.1 (5.3) 28.6 (5.2) 28.6 (5.4)
<25.0 272 (24.1) 245 (21.7) 112 (28.1) 94 (26.2)
25.0–29.9 458 (40.6) 458 (40.6) 159 (40.0) 147 (41.0)
30.0–34.9 266 (23.6) 288 (25.6) 82 (20.6) 81 (22.6)
≥35.0 133 (11.8) 136 (12.1) 45 (11.3) 37 (10.3)
Missing 1 2 1 1
Smoking status at enrollment .70
Never 590 (52.2) 604 (53.5) 228 (57.1) 201 (55.8)
Former 421 (37.3) 429 (38.0) 141 (35.3) 136 (37.8)
Current 119 (10.5) 96 (8.5) 30 (7.5) 23 (6.4)
Pretrial supplements
Multivitamin 633 (56.0) 634 (56.3) 222 (55.6) 222 (61.8) .08
Vitamin D 158 (14.0) 137 (12.2) 66 (16.5) 66 (18.4) .50
Vitamin C 219 (19.4) 271 (24.0) 66 (16.6) 82 (22.8) .03
Zinc 49 (4.3) 38 (3.4) 16 (4.0) 11 (3.1) .48
Serum 25(OH)D at enrollment, ng/mL
Mean 24.6 (8.2) 24.5 (8.5) 24.8 (8.3) 25.3 (8.8) .39
<20 380 (33.6) 402 (35.6) 127 (31.8) 112 (31.1)
20–29.9 474 (42.0) 452 (40.0) 167 (41.9) 151 (41.9)
≥30 276 (24.4) 275 (24.4) 105 (26.3) 97 (26.9)
Serum 25(OH)D, ng/mLd
Mean 31.8 (9.9) 23.9 (8.9) 33.3 (9.9) 25.1 (9.1) <.0001
<20 108 (9.9) 429 (39.0) 25 (6.3) 122 (33.9)
20–29.9 413 (37.7) 431 (39.2) 143 (35.9) 136 (37.8)
≥30 575 (52.5) 239 (21.8) 230 (57.8) 102 (28.3)
Missing 34 30 1 0
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; SD, standard deviation.
a These participants provided symptom data by telephone every 6 months from 2007 to 2012.
b These participants also provided symptom data via daily health diaries from 2009 to 2011.
c P values are shown for comparisons in the Colds and Flu (CAF) substudy participants.
d The blood draw closest in time to the start of participation in the CAF substudy.
1388 • CID 2013:57 (15 November) • Rees et al
We know of 3 previous, high-quality RCTs of vitamin D sup-
plementation that collected URTI symptom data prospectively
from healthy adults. None has shown a significant benefit.
Murdoch et al compared 100 000 IU/month oral vitamin D3 or
placebo for 18 months in 322 adults in New Zealand [9]. This
dose, equivalent to 3300 IU/day, did not significantly reduce
episodes of acute respiratory infection (RR, 0.97; 95% CI, .85–
1.11). In the United States, Li-Ng et al reported 1.4% (95% CI,
−2.4% to 3.4%; P = .57) fewer episodes of URTI in adults given
2000 IU/day vitamin D3 for 12 weeks compared with placebo [10].
This trial may have been underpowered and too short to allow
vitamin D levels to reach a steady state. Laaksi et al compared a
small dose, 400 IU/day vitamin D3 or placebo, for 6 months in
164 Finnish soldiers and reported 2.2 days missed from work
due to respiratory tract infection in the vitamin D group and 3.0
in the placebo group (P = .096) [11].
Trials in other populations have given mixed results. A 1-
year trial of 140 adults at a Swedish immunodeficiency clinic
reported better infection scores in those receiving 4000 IU/day
vitamin D3 than in those receiving placebo (P = .04) [12]. Two
trials in predominantly vitamin D–deficient children in Mon-
golia [13] and Afghanistan [14] showed lower rates of URTI
Table 2. Episodes and Days of Illness of Upper Respiratory Tract Infection





Ratioa (95% CI)Vitamin D Placebo Vitamin D Placebo
Health diary participants (n = 759)
Winter episodes n = 387 n = 351
URTI 275 (71.1%) 252 (71.8%) 0.24 (0.30) 0.27 (0.31) 0.93 (.79–1.09)
Colds 267 (69.0%) 239 (68.1%) 0.22 (0.28) 0.24 (0.31) 0.93 (.78–1.10)
ILI 46 (11.9%) 51 (14.5%) 0.02 (0.09) 0.02 (0.06) 0.95 (.62–1.46)
All seasons episodes n = 399 n = 360
URTI 303 (75.9%) 276 (76.7%) 0.20 (0.26) 0.23 (0.27) 0.94 (.79–1.11)
Colds 295 (73.9%) 266 (73.9%) 0.19 (0.25) 0.21 (0.27) 0.94 (.79–1.12)
ILI 62 (15.5%) 62 (17.2%) 0.02 (0.07) 0.02 (0.04) 0.99 (.68–1.43)
Mean Days Ill per
Person-month (SD)
Adjusted Rate
Ratioa (95% CI)Vitamin D Placebo
Winter days of illness
All days ill 1.78 (3.33) 1.68 (2.84) 1.13 (.90–1.43)
Days of moderate illness 1.70 (3.13) 1.62 (2.80) 1.14 (.90–1.44)
Days of severe illness 0.08 (0.60) 0.06 (0.20) 0.92 (.56–1.50)
All seasons days of illness
All days ill 1.52 (2.98) 1.56 (2.87) 1.03 (.81–1.31)
Days of moderate illness 1.46 (2.79) 1.51 (2.84) 1.04 (.81–1.33)
Days of severe illness 0.06 (0.56) 0.05 (0.20) 0.78 (.49–1.25)
No. Ever Reporting Illness/No.
Odds Ratiob
(95% CI)Vitamin D Placebo
All participants (N = 2228)
Influenza or ILI since last
semiannual phone call
106/1113 (9.5%) 96/1115 (8.6%) 1.14 (.84–1.54)
A cold during the 2 weeks
before semiannual phone
call
423/1113 (38.1%) 417/1111 (37.5%) 1.03 (.87–1.23)
Abbreviations: CI, confidence interval; ILI, influenza-like illness; SD, standard deviation; URTI, upper respiratory tract infection (cold or ILI).
a Intent-to-treat analysis adjusted for study center, follow-up colonoscopy interval, randomization arm (female 2-arm, female 4-arm, male 4-arm), calcium treatment
assignment, season (winter 1, nonwinter [when appropriate], winter 2) and clustering by participant due to longitudinal data.
b Intent-to-treat analysis. Odds ratio adjusted for study center, follow-up colonoscopy interval, and randomization arm (female 2-arm, female 4-arm, male 4-arm).
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and recurrence of pneumonia, respectively, although a later
trial in Afghanistan showed no effect on radiographically con-
firmed pneumonia in children aged <1 year [15]. In 334 healthy
Japanese children, 4 months’ supplementation with 1200 IU/day
vitamin D3 was associated with fewer infections with laboratory-
confirmed influenza A (RR, 0.58; 95% CI, .34–.99), but not with
influenza B or other viruses [16]. Influenza vaccination status
was not assessed in that trial, so it is unclear if that would have
modified the effects of vitamin D supplementation. Other trials
were limited by substantial methodological issues including
retrospective data collection, which can predispose to recall
bias. Two reported a benefit in their primary results [17, 18]
and 2 did not [19, 20]. Thus, several trials suggest a benefit of
vitamin D supplementation on RTI prevention among those
with vitamin D deficiency or other predisposition to infection;
further studies of RTI and potentially other infections could
prove important in those populations. However, it may not be
wise to generalize the results from those who are vitamin D de-
ficient to those who are replete; from children to adults; or from
those with predisposition to infection to those without.
Our negative results were perhaps unexpected in view of pre-
vious observational data suggesting significantly increased risks
of URTI with serum 25(OH)D levels below 16 ng/mL [6], 30
ng/mL [7], or 38 ng/mL [8]. Our data illustrate the potential
for conflicting results between observational studies and ran-
domized trials. In observational analyses, we saw significantly
higher risks of ILI in the lowest quartile of serum 25(OH)D,
whereas the randomized analysis showed no supplementation
benefit in participants whose low serum levels should have put
them at greatest risk. We speculate that observational studies
cannot adequately control unmeasured confounding by exer-
cise, outdoor lifestyle, and other factors. Similar challenges
prevent researchers from understanding whether winter in-
creases in URTI incidence are due to seasonal changes in host
susceptibility, viral transmission, or other factors, and whether
vitamin D plays any role [26].
Our study has the advantages of a large sample size; detailed
reporting of daily symptoms using health diaries in a large sub-
group during an average of 13 months’ observation including 2
winter seasons; serum 25(OH)D measurements; excellent ad-
herence to pill-taking; and use of a common route and dose of
supplementation. All participants were randomized for at least
12 months before completing symptom diaries, so failure to
attain a steady state did not account for our negative findings.
We present extensive sensitivity analyses and other secondary
data to support our primary results; these include semiannual
Table 3. Serum 25-Hydroxy Vitamin D and Risk of Upper Respiratory Tract Infection in Health Diary Participants (n = 758)
Episodes
All
Rate Ratioa (95% CI)
Quartiles of Serum Vitamin D Closest to 1 November 2009b




URTI 0.93 (.86–1.01) 1.0 0.94 (.74–1.19) 0.97 (.76–1.23) 0.86 (.68–1.10) .66
Colds 0.94 (.87–1.02) 1.0 1.01 (.79–1.30) 1.01 (.79–1.29) 0.92 (.72–1.18) .83
ILI 0.87 (.68–1.10) 1.0 0.41 (.23–0.73) 0.70 (.39–1.25) 0.50 (.27–.94) .01
All seasons
URTI 0.91 (.83–.99) 1.0 0.87 (.66–1.13) 0.86 (.66–1.12) 0.79 (.61–1.02) .34
Colds 0.91 (.83–1.00) 1.0 0.91 (.69–1.20) 0.90 (.68–1.18) 0.82 (.63–1.07) .54
ILI 0.84 (.68–1.04) 1.0 0.47 (.28–.78) 0.59 (.36–.98) 0.51 (.30–.85) .01
Days of illness
Winter
Any 0.96 (.85–1.10) 1.0 0.96 (.65–1.40) 1.07 (.73–1.57) 0.91 (.61–1.34) .79
Moderate 0.97 (.85–1.11) 1.0 0.97 (.66–1.43) 1.10 (.74–1.63) 0.93 (.62–1.40) .78
Severe 0.84 (.63–1.11) 1.0 0.58 (.30–1.12) 0.60 (.32–1.12) 0.49 (.24–.99) .13
All seasons
Any 0.95 (.84–1.07) 1.0 0.90 (.60–1.34) 0.96 (.66–1.46) 0.86 (.58–1.27) .85
Moderate 0.95 (.84–1.08) 1.0 0.91 (.61–1.37) 0.99 (.67–1.45) 0.87 (.59–1.30) .86
Severe 0.82 (.63–1.07) 1.0 0.52 (.28–.95) 0.52 (.29–.92) 0.49 (.26–.91) .04
Abbreviations: CI, confidence interval; ILI, influenza-like illness; RR, rate ratio; URTI, upper respiratory tract infection (cold or ILI).
a Rate ratio per 10 ng/mL change in serum 25-hydroxy vitamin D, adjusted for season of closest blood draw (December–February, March–May, June–August,
September–November), age, sex, race (white, black, Asian, other), Hispanic ethnicity, body mass index, northern latitude, smoking status (never, former, current),
activity level (low, moderate, high), artificial tanning (no/yes), total annual vacation days in a warm climate.
b Quartiles based on distribution of 758 participants: 25th, 50th, and 75th percentiles (21.75, 28.42, 35.4 ng/mL).
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surveys of 2228 randomized participants over multiple seasons,
which, although potentially susceptible to recall bias, also show
no significant association between vitamin D supplementation
and either colds or ILI.
A limitation of our study was the collection of health diaries
from only one-third of the participants randomized in the
parent trial; nevertheless, all participants were invited to take
part irrespective of adherence to pill taking, and 759 partici-
pants gave sufficient power to identify relative risks of 0.7 for
URTI episodes and 0.8 for duration. It is possible, but unlikely,
that self-selection of participants from the parent study was in-
fluenced by any early effect (or lack of effect) of study treatment
on URTI symptoms. Limitations in some of our analyses
include our use of semiannual self-reported adherence to pill-
taking; lack of laboratory confirmation of URTI; and potential
misclassification of colds and ILI by symptom-based case defi-
nitions.
CONCLUSIONS
Supplementation with 1000 IU/day vitamin D3 supplementa-
tion conferred no significant benefit on the incidence, duration,
or severity of URTI symptoms in our study population of
adults aged 45 years and older without preexisting vitamin D
deficiency. Our results suggest that supplementation at this
level, or by inference, at the level of the Recommended Dietary
Allowance in North America [27] and the European Union [28],
and contained in many commonly used supplements, is unlikely
to have any noticeable benefit in URTI prevention in the non-
deficient adult population. The effects on URTI of supplemen-
tation in adults with vitamin D deficiency (<12 ng/mL) should
be addressed in future trials.
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